UNITEDHEALTH GROUP INC

UnitedHealth’s stock soars after BofA and Morgan Stanley upgrade to Buy, lift target prices to $450–$453, and a 5% dividend hike, boosting investor confidence and market gains.

UnitedHealth Group Q1 earnings dip forecasted, insiders buying shares and Morgan Stanley upgrade suggest mixed signals—watch for rebound potential.

UnitedHealth Group’s rally amid regulatory scrutiny: Q4 earnings drop, ACA rebate plans, and investor sentiment reveal why the $321 billion insurer remains a resilient market leader.

UnitedHealth’s 36% share slide sparks analyst debate – despite regulatory, cyber, and Medicare scrutiny, investors eye a 2026 rebound with a $444 target.

UnitedHealth Group faces regulatory scrutiny over Medicare reimbursement tactics, amid investor doubts and a looming earnings release that could shape its future.

UnitedHealth Group Inc. reported a strong third-quarter earnings beat, driven by performance in its Optum and UnitedHealthcare segments, and raised its 2025 earnings-per-share guidance, sparking renewed interest in the healthcare sector.

UnitedHealth Group Inc. is poised to release its third-quarter earnings on October 28, 2025, with analysts expecting the company to beat forecasts and drive stock growth, amidst strategic initiatives and cost-control measures.

Despite recent volatility and a 30% year-to-date decline, UnitedHealth Group’s underlying fundamentals and bullish analyst coverage suggest a potential rebound ahead of the October 28 rally, driven by the company’s resilient business model and expan…

UnitedHealth Group, the largest US health insurer, is under investigation by the US Department of Justice over its Medicare practices, causing a 2.43% decline in its stock.

UnitedHealth Group Inc. stock has seen significant market movements and insider buying activity, with top analysts and executives signaling confidence in the company’s future despite a tumultuous recent performance.